Mabwell(SH:688062) Zheng Quan Zhi Xing·2025-07-15 10:26Core Viewpoint - The company has signed an exclusive licensing agreement with CALICO LIFE SCIENCES LLC for the development, production, and commercialization of IL-11 targeted therapies outside of Greater China, which is expected to enhance its clinical research and long-term development strategy [5][8]. Group 1: Licensing Agreement Details - The agreement allows CALICO to exclusively develop, produce, and commercialize the licensed products in all regions except Greater China [5][7]. - The company will receive an upfront payment of $25 million and potential milestone payments totaling up to $571 million, along with tiered royalties based on net sales of the licensed products [7][8]. - The agreement is not classified as a related party transaction and does not constitute a major asset restructuring as per relevant regulations [5][8]. Group 2: Company and Partner Information - CALICO LIFE SCIENCES LLC, founded in September 2013, focuses on aging biology and age-related diseases, aiming to enhance understanding of biological mechanisms controlling human aging [5][6]. - The CEO of CALICO is Arthur D. Levinson, and the company operates from South San Francisco, California [5][6]. Group 3: Agreement Conditions and Impact - The agreement will take effect upon approval at the company's shareholder meeting and is governed by California law [7][8]. - The collaboration is expected to leverage both parties' strengths, promoting resource sharing and mutual benefits, while not affecting the company's main business or independence [8].